Brixadi (buprenorphine) is a prescription injection that’s used to treat opioid use disorder (OUD). It comes as a solution in prefilled syringes and is given weekly or monthly by a healthcare ...

Brixadi (buprenorphine) is a prescription drug that’s used to treat opioid use disorder (OUD). Brixadi comes as a liquid solution in a prefilled syringe. You’ll receive Brixadi as an injection under ...

Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...

Credit: Braeburn. Brixadi is supplied as prefilled single-dose syringes in weekly (8mg, 16mg, 24mg, 32mg) and monthly (64mg, 96mg, 128mg) doses. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...

Brixadi (buprenorphine) is a brand-name injection that’s prescribed for opioid use disorder. As with other drugs, Brixadi can cause side effects, such as injection site reactions and respiratory ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

Keep reading for specific information about the dosage of Brixadi, including its strengths and how the medication is given. For a comprehensive look at Brixadi, see this article. Note: This article ...

SILVER SPRING, Md., May 23, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat ...